Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

The PARP-1 inhibitor Olaparib suppresses BRCA1 protein levels, increases apoptosis and causes radiation hypersensitivity in BRCA1+/- lymphoblastoid cells.

Bourton EC, Ahorner PA, Plowman PN, Zahir SA, Al-Ali H, Parris CN.

J Cancer. 2017 Oct 23;8(19):4048-4056. doi: 10.7150/jca.21338. eCollection 2017.

2.

Increased γ-H2AX and Rad51 DNA Repair Biomarker Expression in Human Cell Lines Resistant to the Chemotherapeutic Agents Nitrogen Mustard and Cisplatin.

Adam-Zahir S, Plowman PN, Bourton EC, Sharif F, Parris CN.

Chemotherapy. 2014;60(5-6):310-20. doi: 10.1159/000430086. Epub 2015 Jul 1.

PMID:
26138778
3.

Enhanced γ-H2AX DNA damage foci detection using multimagnification and extended depth of field in imaging flow cytometry.

Parris CN, Adam Zahir S, Al-Ali H, Bourton EC, Plowman C, Plowman PN.

Cytometry A. 2015 Aug;87(8):717-23. doi: 10.1002/cyto.a.22697. Epub 2015 Jun 18.

4.

Elevated expression of artemis in human fibroblast cells is associated with cellular radiosensitivity and increased apoptosis.

Ulus-Senguloglu G, Arlett CF, Plowman PN, Parnell J, Patel N, Bourton EC, Parris CN.

Br J Cancer. 2012 Oct 23;107(9):1506-13. doi: 10.1038/bjc.2012.443.

5.

Multispectral imaging flow cytometry reveals distinct frequencies of γ-H2AX foci induction in DNA double strand break repair defective human cell lines.

Bourton EC, Plowman PN, Zahir SA, Senguloglu GU, Serrai H, Bottley G, Parris CN.

Cytometry A. 2012 Feb;81(2):130-7. doi: 10.1002/cyto.a.21171. Epub 2011 Dec 13.

6.

Prolonged expression of the γ-H2AX DNA repair biomarker correlates with excess acute and chronic toxicity from radiotherapy treatment.

Bourton EC, Plowman PN, Smith D, Arlett CF, Parris CN.

Int J Cancer. 2011 Dec 15;129(12):2928-34. doi: 10.1002/ijc.25953. Epub 2011 Apr 13.

7.

A novel splice variant of the DNA-PKcs gene is associated with clinical and cellular radiosensitivity in a patient with xeroderma pigmentosum.

Abbaszadeh F, Clingen PH, Arlett CF, Plowman PN, Bourton EC, Themis M, Makarov EM, Newbold RF, Green MH, Parris CN.

J Med Genet. 2010 Mar;47(3):176-81. doi: 10.1136/jmg.2009.068866. Epub 2009 Sep 24.

8.

Chemosensitivity of primary human fibroblasts with defective unhooking of DNA interstrand cross-links.

Clingen PH, Arlett CF, Hartley JA, Parris CN.

Exp Cell Res. 2007 Feb 15;313(4):753-60. Epub 2006 Nov 18.

PMID:
17188678
9.

Clinical and cellular ionizing radiation sensitivity in a patient with xeroderma pigmentosum.

Arlett CF, Plowman PN, Rogers PB, Parris CN, Abbaszadeh F, Green MH, McMillan TJ, Bush C, Foray N, Lehmann AR.

Br J Radiol. 2006 Jun;79(942):510-7.

PMID:
16714754
10.

Heterogeneity of dimer excision in young and senescent human dermal fibroblasts.

Boyle J, Kill IR, Parris CN.

Aging Cell. 2005 Oct;4(5):247-55.

11.

The manipulation of chromosomes by mankind: the uses of microcell-mediated chromosome transfer.

Meaburn KJ, Parris CN, Bridger JM.

Chromosoma. 2005 Sep;114(4):263-74. Epub 2005 Oct 15. Review.

PMID:
16133353
12.

Telomerase activity in the human breast.

Mokbell K, Parris CN, Ghilchik M, Newbold RF.

Breast. 1999 Aug;8(4):208-11.

PMID:
14731443
13.

Complete non-puerperial uterine inversion as a result of a uterine sarcoma.

Rattray CA, Parris CN, Chisholm G, Coard KC.

West Indian Med J. 2000 Sep;49(3):245-7.

PMID:
11076223
14.

Telomerase activity and lymphovascular invasion in breast cancer.

Mokbel KM, Parris CN, Ghilchik M, Amerasinghe CN, Newbold RF.

Eur J Surg Oncol. 2000 Feb;26(1):30-3.

PMID:
10718176
15.

The association between telomerase, histopathological parameters, and KI-67 expression in breast cancer.

Mokbel K, Parris CN, Ghilchik M, Williams G, Newbold RF.

Am J Surg. 1999 Jul;178(1):69-72.

PMID:
10456708
16.

Telomerase activity in phyllodes tumours.

Mokbel K, Ghilchik M, Parris CN, Newbold RF.

Eur J Surg Oncol. 1999 Aug;25(4):352-5.

PMID:
10419703
17.

Telomerase activity in melanoma and non-melanoma skin cancer.

Parris CN, Jezzard S, Silver A, MacKie R, McGregor JM, Newbold RF.

Br J Cancer. 1999 Jan;79(1):47-53.

18.

Telomerase activity and prognosis in breast cancer.

Mokbel K, Parris CN, Radbourne R, Ghilchik M, Newbold RF.

Eur J Surg Oncol. 1999 Jun;25(3):269-72.

PMID:
10336806
19.

Functional evidence of novel tumor suppressor genes for cutaneous malignant melanoma.

Parris CN, Harris JD, Griffin DK, Cuthbert AP, Silver AJ, Newbold RF.

Cancer Res. 1999 Feb 1;59(3):516-20.

20.

ERCC4 (XPF) encodes a human nucleotide excision repair protein with eukaryotic recombination homologs.

Brookman KW, Lamerdin JE, Thelen MP, Hwang M, Reardon JT, Sancar A, Zhou ZQ, Walter CA, Parris CN, Thompson LH.

Mol Cell Biol. 1996 Nov;16(11):6553-62.

21.

Xeroderma pigmentosum and related disorders: examining the linkage between defective DNA repair and cancer.

Kraemer KH, Levy DD, Parris CN, Gozukara EM, Moriwaki S, Adelberg S, Seidman MM.

J Invest Dermatol. 1994 Nov;103(5 Suppl):96S-101S. Review.

22.

The human DNA repair gene, ERCC2 (XPD), corrects ultraviolet hypersensitivity and ultraviolet hypermutability of a shuttle vector replicated in xeroderma pigmentosum group D cells.

Gözükara EM, Parris CN, Weber CA, Salazar EP, Seidman MM, Watkins JF, Prakash L, Kraemer KH.

Cancer Res. 1994 Jul 15;54(14):3837-44.

23.
25.

Hypersensitivity of human testis-tumour cell lines to chemotherapeutic drugs.

Masters JR, Osborne EJ, Walker MC, Parris CN.

Int J Cancer. 1993 Jan 21;53(2):340-6.

PMID:
8425772
26.
27.

Ultraviolet mutagenesis in human lymphocytes: the effect of cellular transformation.

Parris CN, Kraemer KH.

Exp Cell Res. 1992 Aug;201(2):462-9.

PMID:
1322318
28.

pSV3neo transfection and radiosensitivity of human cancer cell lines.

Parris CN, Masters JR, Green MH.

Cancer Lett. 1990 Dec 3;55(2):171-5.

PMID:
2176129
30.

Differential sensitivities to gamma radiation of human bladder and testicular tumour cell lines.

Parris CN, Arlett CF, Lehmann AR, Green MH, Masters JR.

Int J Radiat Biol Relat Stud Phys Chem Med. 1988 Apr;53(4):599-608.

PMID:
2832339
31.

Intravesical chemotherapy: combination with dimethyl sulfoxide does not enhance cytotoxicity in vitro.

Walker L, Walker MC, Parris CN, Masters JR.

Urol Res. 1988;16(4):329-31.

PMID:
3176208
32.

Differential sensitivities of human testicular and bladder tumor cell lines to chemotherapeutic drugs.

Walker MC, Parris CN, Masters JR.

J Natl Cancer Inst. 1987 Aug;79(2):213-6.

PMID:
3474453
33.

Intravesical chemotherapy: combination with Tween 80 increases cytotoxicity in vitro.

Parris CN, Masters JR, Walker MC, Newman B, Riddle P, English P.

Urol Res. 1987;15(1):17-20.

PMID:
3103302
34.

Intravesical chemotherapy: in vitro studies on the relationship between dose and cytotoxicity.

Walker MC, Masters JR, Parris CN, Hepburn PJ, English PJ.

Urol Res. 1986;14(3):137-40.

PMID:
3092427

Supplemental Content

Loading ...
Support Center